Chardan Engaged to Facilitate Nocturne Acquisition Corporation’s Business Combination with Cognos Therapeutics
WILMINGTON, Del. and INGLEWOOD, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE)
Nocturne Acquisition Corporation (NASDAQ:MBTC, MBTCU, MBTCR) (“Nocturne”) and Cognos Therapeutics, Inc. (“Cognos”) have made a significant announcement today with the engagement of Chardan, a leading global investment bank, in the role of capital markets advisor to Nocturne for their highly anticipated business combination transaction, known as the Business Combination. This development marks a crucial step in the strategic partnership between Nocturne and Cognos, setting the stage for future growth and innovation in the biopharmaceutical industry.
The Partnership and Business Combination
The collaboration between Nocturne Acquisition Corporation and Cognos Therapeutics, Inc. represents a dynamic synergy of resources and expertise in the healthcare sector. With Chardan’s involvement as the capital markets advisor, the Business Combination is expected to create a powerhouse in the biopharmaceutical field, poised to deliver cutting-edge solutions and drive value for shareholders. The strategic alignment of Nocturne and Cognos underscores a shared commitment to advancing healthcare technologies and enhancing patient care.
Through this partnership, Nocturne aims to leverage Cognos’ innovative research and development pipeline to accelerate the delivery of breakthrough therapies to patients worldwide. By combining forces, Nocturne and Cognos seek to maximize their collective strengths and capabilities, paving the way for transformative advancements in the treatment of various diseases and medical conditions.
Impact on Individuals
For individuals, this partnership and impending business combination hold the promise of new treatment options and improved healthcare outcomes. Patients may benefit from access to groundbreaking therapies resulting from the combined expertise of Nocturne and Cognos. The collaboration between these two entities could potentially revolutionize the healthcare landscape, offering hope and healing to those in need.
Impact on the World
On a global scale, the strategic partnership between Nocturne Acquisition Corporation and Cognos Therapeutics, Inc. has the potential to drive innovation and progress in the biopharmaceutical industry. By pooling their resources and knowledge, Nocturne and Cognos may introduce novel solutions that address unmet medical needs and contribute to the advancement of healthcare on a worldwide level. This collaboration underscores the importance of collaboration and shared vision in shaping the future of healthcare.
Conclusion
In conclusion, the engagement of Chardan as the capital markets advisor in the Business Combination between Nocturne Acquisition Corporation and Cognos Therapeutics, Inc. marks a significant milestone in the evolution of the biopharmaceutical industry. This strategic partnership has the potential to bring about transformative changes in healthcare delivery and patient care, benefiting individuals and communities alike. As Nocturne and Cognos join forces to drive innovation and progress, the implications of their collaboration are far-reaching and hold the promise of a brighter future for healthcare.
